The antiproliferative effect of PS-modified SL2-B aptamer is sequence specific

The antiproliferative effect of PS-modified SL2-B aptamer is sequence specific, a scrambled sequence was added to the Hep G2 cells at the same concentration as PSmodified SL2-B (Figure 5). The results showed minimal decrease on the cell proliferation with the scrambled sequence, confirming that the inhibitory effect on VEGF165 protein activity by PSmodified SL2-B was sequence specific in Hep G2 cells. The sequence specific inhibition was also confirmed by the cell count and morphological differences presented in photomicrographs (Figure 6). As shown in Figure 6A and 6B, the cells treated with modified sequence have noticeably fewer cells as compared with the scrambled sequence where there appears to be more cells per view and packed closely to one another. Furthermore, under the same magnification, the morphology of the cells treated with the modified sequence appears longer and thinner with many side projections as compared with the scrambled sequence, which are more angular and more defined in shape (Figure 6C and 6D). These findings indicate the potential of the PS-modified SL2-B aptamer sequence in inhibiting the Hep G2 cancer cells proliferation strongly and specifically. To determine the cell death mechanism in Hep G2 cells, annexin V apoptosis assay was performed and HIV-1 integrase inhibitor 2 analyzed using flow cytometry. In Figure 7A, the R9 and R11 quadrant cells in flow cytometry scatterplot were counted and expressed as percentage of cells in late and early apoptosis phase respectively. Early apoptotic cells include cell population that is annexin V positive only (R11),Antiproliferative Activity of Aptamer on Cancererative activity in Hep G2 cells not only by inhibiting VEGF pathway but also the interconnected delta/jagged-notch signaling pathway in Hep G2 cells. IKK 16 web further studies are warranted to determine the effect of the modified aptamer on different notch ligands and other VEGF linked 1531364 signaling pathways.aptamer sequence can potentially be useful in oligomer-based cancer therapeutic applications, though further preclinical studies are required for better understanding of the SL2-B aptamer sequence and to evaluate its potential therapeutic value for cancer treatment.ConclusionsTo summarize, this work attempted to study the antiproliferative potential of SL2-B aptamer in cancer cells. From the data, we conclude that post-modification, the PS-modified SL2-B aptamer retained its binding affinity and specificity for the heparin-binding domain (HBD) of VEGF165 protein. Furthermore, compared to the unmodified aptamer, the modified SL2-B demonstrated good biostability and exhibited its sequence specific antiproliferative activity on Hep G2 cancer cells in hypoxia conditions. Thus, based on the results of this work, it appears that chemical modification can be a useful approach in prolonging the half-life of the SL2-B aptamer in the in vitro conditions. This newly obtained SL2-BAcknowledgmentsThe authors thank Dr Tong Yen Wah (Department of Chemical and Biomolecular engineering, National University of Singapore) for providing the Hep G2 cancer cells.Author ContributionsConceived and designed the experiments: HK JJL BHB LLY. Performed the experiments: HK JJL. Analyzed the data: HK JJL BHB LLY. Contributed reagents/materials/analysis tools: HK JJL LLY. Wrote the paper: HK JJL LLY.
The cornea is our transparent window to the world and its integrity and transparency are essential for proper functioning of the eye. The cornea is a highly organised tissue with thr.The antiproliferative effect of PS-modified SL2-B aptamer is sequence specific, a scrambled sequence was added to the Hep G2 cells at the same concentration as PSmodified SL2-B (Figure 5). The results showed minimal decrease on the cell proliferation with the scrambled sequence, confirming that the inhibitory effect on VEGF165 protein activity by PSmodified SL2-B was sequence specific in Hep G2 cells. The sequence specific inhibition was also confirmed by the cell count and morphological differences presented in photomicrographs (Figure 6). As shown in Figure 6A and 6B, the cells treated with modified sequence have noticeably fewer cells as compared with the scrambled sequence where there appears to be more cells per view and packed closely to one another. Furthermore, under the same magnification, the morphology of the cells treated with the modified sequence appears longer and thinner with many side projections as compared with the scrambled sequence, which are more angular and more defined in shape (Figure 6C and 6D). These findings indicate the potential of the PS-modified SL2-B aptamer sequence in inhibiting the Hep G2 cancer cells proliferation strongly and specifically. To determine the cell death mechanism in Hep G2 cells, annexin V apoptosis assay was performed and analyzed using flow cytometry. In Figure 7A, the R9 and R11 quadrant cells in flow cytometry scatterplot were counted and expressed as percentage of cells in late and early apoptosis phase respectively. Early apoptotic cells include cell population that is annexin V positive only (R11),Antiproliferative Activity of Aptamer on Cancererative activity in Hep G2 cells not only by inhibiting VEGF pathway but also the interconnected delta/jagged-notch signaling pathway in Hep G2 cells. Further studies are warranted to determine the effect of the modified aptamer on different notch ligands and other VEGF linked 1531364 signaling pathways.aptamer sequence can potentially be useful in oligomer-based cancer therapeutic applications, though further preclinical studies are required for better understanding of the SL2-B aptamer sequence and to evaluate its potential therapeutic value for cancer treatment.ConclusionsTo summarize, this work attempted to study the antiproliferative potential of SL2-B aptamer in cancer cells. From the data, we conclude that post-modification, the PS-modified SL2-B aptamer retained its binding affinity and specificity for the heparin-binding domain (HBD) of VEGF165 protein. Furthermore, compared to the unmodified aptamer, the modified SL2-B demonstrated good biostability and exhibited its sequence specific antiproliferative activity on Hep G2 cancer cells in hypoxia conditions. Thus, based on the results of this work, it appears that chemical modification can be a useful approach in prolonging the half-life of the SL2-B aptamer in the in vitro conditions. This newly obtained SL2-BAcknowledgmentsThe authors thank Dr Tong Yen Wah (Department of Chemical and Biomolecular engineering, National University of Singapore) for providing the Hep G2 cancer cells.Author ContributionsConceived and designed the experiments: HK JJL BHB LLY. Performed the experiments: HK JJL. Analyzed the data: HK JJL BHB LLY. Contributed reagents/materials/analysis tools: HK JJL LLY. Wrote the paper: HK JJL LLY.
The cornea is our transparent window to the world and its integrity and transparency are essential for proper functioning of the eye. The cornea is a highly organised tissue with thr.